Which has preferable earnings & valuation, ACRV or PASG?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is ACRV or PASG more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Passage Bio N/A -150.88% -59.78%

Does the media favor ACRV or PASG?

In the previous week, Passage Bio had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.93 beat Passage Bio's score of 0.45 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Passage Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PASG or PLRX?

Pliant Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Pliant Therapeutics N/A N/A -$149.34M -$1.84 N/A

Is PASG or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Pliant Therapeutics N/A -58.11% -44.37%

Does the media refer more to PASG or PLRX?

In the previous week, Passage Bio had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Passage Bio's score of 0.45 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XBIT or PASG?

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has better valuation & earnings, XBIT or PASG?

XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is XBIT or PASG more profitable?

XBiotech's return on equity of -26.10% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Passage Bio N/A -150.88% -59.78%

Do analysts prefer PASG or CYPH?

Passage Bio currently has a consensus price target of $13.25, suggesting a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Passage Bio is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PASG or CYPH?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is PASG or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Cypherpunk Technologies N/A -48.33% -42.21%

Is PASG or MCRB more profitable?

Seres Therapeutics' return on equity of -130.29% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Seres Therapeutics N/A -130.29% -35.35%

Does the media prefer PASG or MCRB?

In the previous week, Seres Therapeutics had 5 more articles in the media than Passage Bio. MarketBeat recorded 12 mentions for Seres Therapeutics and 7 mentions for Passage Bio. Seres Therapeutics' average media sentiment score of 1.03 beat Passage Bio's score of 0.45 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Passage Bio (PASG) Competitors

$4.85 +0.15 (+3.19%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$4.84 0.00 (-0.10%)

As of 06/29/2026 07:38 PM Eastern

Compare

PASG vs. ACRV, PLRX, XBIT, CYPH, and MCRB

Should you buy Passage Bio stock or one of its competitors? MarketBeat compares Passage Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Passage Bio include Acrivon Therapeutics (ACRV), Pliant Therapeutics (PLRX), XBiotech (XBIT), Cypherpunk Technologies (CYPH), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Passage Bio compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Passage Bio had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.93 beat Passage Bio's score of 0.45 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Acrivon Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Acrivon Therapeutics' return on equity of -64.43% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Passage Bio	N/A	-150.88%	-59.78%

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 555.43%. Passage Bio has a consensus price target of $13.25, suggesting a potential upside of 173.20%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Acrivon Therapeutics beats Passage Bio on 10 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Pliant Therapeutics?

Passage Bio (NASDAQ:PASG) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Passage Bio had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Passage Bio and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Passage Bio's score of 0.45 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Passage Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Pliant Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Passage Bio currently has a consensus target price of $13.25, indicating a potential upside of 173.20%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 160.87%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Pliant Therapeutics' return on equity of -58.11% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Summary

Passage Bio beats Pliant Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Passage Bio compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Passage Bio had 6 more articles in the media than XBiotech. MarketBeat recorded 7 mentions for Passage Bio and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Passage Bio's score of 0.45 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
Passage Bio	Neutral

XBiotech is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

XBiotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

XBiotech's return on equity of -26.10% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Passage Bio	N/A	-150.88%	-59.78%

55.7% of XBiotech shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 30.8% of XBiotech shares are held by company insiders. Comparatively, 4.9% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Passage Bio beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Cypherpunk Technologies?

Passage Bio (NASDAQ:PASG) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Cypherpunk Technologies' return on equity of -48.33% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

In the previous week, Passage Bio had 6 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 7 mentions for Passage Bio and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Passage Bio's score of 0.45 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Passage Bio	Neutral
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Passage Bio currently has a consensus price target of $13.25, suggesting a potential upside of 173.20%. Given Passage Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Passage Bio is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Passage Bio has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Passage Bio beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Passage Bio compare to Seres Therapeutics?

Passage Bio (NASDAQ:PASG) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Passage Bio has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Seres Therapeutics' return on equity of -130.29% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Seres Therapeutics	N/A	-130.29%	-35.35%

Passage Bio presently has a consensus target price of $13.25, indicating a potential upside of 173.20%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 118.23%. Given Passage Bio's higher possible upside, research analysts plainly believe Passage Bio is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Seres Therapeutics had 5 more articles in the media than Passage Bio. MarketBeat recorded 12 mentions for Seres Therapeutics and 7 mentions for Passage Bio. Seres Therapeutics' average media sentiment score of 1.03 beat Passage Bio's score of 0.45 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has higher revenue and earnings than Passage Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Seres Therapeutics	$790K	95.45	$5.70M	-$5.17	N/A

Summary

Seres Therapeutics beats Passage Bio on 10 of the 13 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PASG vs. The Competition

Export

Metric	Passage Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.08M	$3.62B	$6.85B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.41	20.93	26.04	24.36
Price / Sales	N/A	345.92	550.14	102.43
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.82	8.71	10.98	6.49
Net Income	-$45.52M	$23.87M	$3.57B	$336.61M
7 Day Performance	-20.75%	3.59%	2.60%	1.25%
1 Month Performance	-15.94%	1.73%	0.93%	0.24%
1 Year Performance	-39.42%	69.03%	36.40%	30.16%

Passage Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PASG Passage Bio	4.5213 of 5 stars	$4.85 +3.2%	$13.25 +173.2%	-26.8%	$15.08M	N/A	N/A	130	Insider Trade Gap Down
ACRV Acrivon Therapeutics	2.0177 of 5 stars	$1.69 +6.6%	$11.67 +592.4%	+48.3%	$72.12M	N/A	N/A	58	News Coverage
PLRX Pliant Therapeutics	2.6823 of 5 stars	$1.17 +0.4%	$3.00 +157.5%	-8.0%	$71.83M	$1.58M	N/A	90	News Coverage
XBIT XBiotech	0.8263 of 5 stars	$2.33 +0.9%	N/A	-16.8%	$71.04M	N/A	N/A	100
CYPH Cypherpunk Technologies	0.653 of 5 stars	$0.67 -9.7%	N/A	+142.7%	$70.84M	N/A	N/A	40	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PASG) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Passage Bio (PASG) Competitors

PASG vs. ACRV, PLRX, XBIT, CYPH, and MCRB

How does Passage Bio compare to Acrivon Therapeutics?

Summary

How does Passage Bio compare to Pliant Therapeutics?

Summary

How does Passage Bio compare to XBiotech?

Summary

How does Passage Bio compare to Cypherpunk Technologies?

Summary

How does Passage Bio compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Passage Bio (PASG) Competitors

PASG vs. ACRV, PLRX, XBIT, CYPH, and MCRB

How does Passage Bio compare to Acrivon Therapeutics?

Does the media favor ACRV or PASG?

Which has preferable earnings & valuation, ACRV or PASG?

Which has more volatility & risk, ACRV or PASG?

Do institutionals & insiders have more ownership in ACRV or PASG?

Is ACRV or PASG more profitable?

Do analysts prefer ACRV or PASG?

Summary

How does Passage Bio compare to Pliant Therapeutics?

Does the media refer more to PASG or PLRX?

Which has more volatility and risk, PASG or PLRX?

Which has preferable earnings & valuation, PASG or PLRX?

Do institutionals and insiders have more ownership in PASG or PLRX?

Do analysts prefer PASG or PLRX?

Is PASG or PLRX more profitable?

Summary

How does Passage Bio compare to XBiotech?

Do analysts rate XBIT or PASG?

Does the media prefer XBIT or PASG?

Which has better valuation & earnings, XBIT or PASG?

Which has more risk and volatility, XBIT or PASG?

Is XBIT or PASG more profitable?

Do institutionals and insiders hold more shares of XBIT or PASG?

Summary

How does Passage Bio compare to Cypherpunk Technologies?

Is PASG or CYPH more profitable?

Does the media prefer PASG or CYPH?

Which has preferable valuation & earnings, PASG or CYPH?

Do analysts prefer PASG or CYPH?

Which has more volatility and risk, PASG or CYPH?

Do insiders & institutionals hold more shares of PASG or CYPH?

Summary

How does Passage Bio compare to Seres Therapeutics?

Which has more risk & volatility, PASG or MCRB?

Do institutionals and insiders have more ownership in PASG or MCRB?

Is PASG or MCRB more profitable?

Do analysts prefer PASG or MCRB?

Does the media prefer PASG or MCRB?

Which has preferable valuation and earnings, PASG or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG vs. The Competition

Passage Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools